



DT07 Rec'd PTO 26 JAN 2005

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Peggy Wingard et al.

Application No. 10/509,627

Filed: September 29, 2004

For: PHARMACEUTICAL
COMPOSITIONS CONTAINING
WATER-SOLUBLE PRODRUGS
OF PROPOFOL AND METHODS
OF ADMINISTERING SAME

:
:
: Confirmation No.: TBD
:
: Group Art Unit: TBD
:
: Examiner: TBD
:
: Atty Docket: 006050.00067

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Pursuant to the duty of disclosure under 37 CFR §§ 1.56 and 1.97-1.98, the documents listed on the attached forms PTO/SB/08a and PTO/SB/08b are being brought to the attention of the Examiner in charge of the above-identified application. Copies of the foreign documents and the non-U.S. patent literature documents are enclosed.

The Examiner is respectfully requested to initial the space adjacent the document entries on forms PTO/SB/08a and PTO/SB/08b and to return a copy of the initialed forms to confirm that the documents have been considered and have been officially made of record in this application.

If the Examiner has any questions or wishes to discuss this application, the Examiner is invited to telephone the undersigned representative at the number set forth below.


The accompanying Information Disclosure Statement is being filed before the issuance of a first action. Therefore, no fee is believed due at this time. However, the Commissioner is authorized to charge any fees that may be required to our Deposit Account No. 19-0733.

Respectfully submitted,


BANNER & WITCOFF, LTD.

Date: January 26, 2005

1001 G Street N.W.
11th Floor
Washington, D.C. 20001
(202) 824-3000

By: 

Paul M. Rivard
Registration No. 43,446



PCT

TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

Application Number	10/509,627	
Filing Date	09/29/2004	
First Named Inventor	Peggy Wingard et al.	
Art Unit	TBD	
Examiner Name	TBD	
Total Number of Pages in This Submission	Attorney Docket Number	006050.00067

ENCLOSURES (check all that apply)

<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment / Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Reply to Missing Parts/ Incomplete Application <input type="checkbox"/> Reply to Missing Parts under 37 CFR1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) ____ <input type="checkbox"/> Landscape Table on CD	<input type="checkbox"/> After Allowance Communication to TC <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): PTO/SB/08a; 4 PTO/SB/08b; 2 foreign references and 38 non-U.S. patent documents
Remarks		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm	Banner & Witcoff, LTD.		
Signature			
Printed Name	Paul M. Rivard		
Date	January 26, 2004	Reg. No.	43,446

CERTIFICATE OF TRANSMISSION/MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.

Signature			
Typed or printed name		Date	

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.


Complete if Known

Application Number	10/509,627
Filing Date	09/29/04
First Named Inventor	Peggy Wingard et
Art Unit	TBD
Examiner Name	TBD
Attorney Docket Number	006050.00067

(Use as many sheets as necessary)

Sheet	1	of	5
-------	---	----	---

Attorney Docket Number	006050.00067
------------------------	--------------

[illegible][illegible]


**Examiner
Signature**

Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number	10/509,627
Filing Date	09/29/04
First Named Inventor	Peggy Wingard et al.
Art Unit	TBD
Examiner Name	TBD
Attorney Docket Number	006050.00067

Sheet 2 of 5

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		"Product Identification Guide," PDR, 52 Edition, 1998, Physicians' Desk Reference, pg. 343	
		"Zeneca Pharmaceuticals," PDR, 52 Edition, 1998, Physicians' Desk Reference, pgs. 3157-3163	
		AGALLOCO, JAMES, "Steam Sterilization and Steam Quality," January-February 2000, pgs. 59-63, Vol. 54, No. 1, Agalocco and Associates, Belle Mead, NJ	
		BALOUGH, VALÉRIA, PÉTIZON, MARCEL, and GOLFIER, MICHAEL, "Oxidations with Silver Carbonate/Celite. V. Oxidations of Phenols and Related Compounds," J. Org. Chem., 1971, pgs. 1339-1341, Vol. 36, No. 10, Laboratoire de Stéréochimie, Faculté des Sciences, 91 Orsay, France	
		BERNSTEIN, DAVID F., PhD, and HAMRELL, MICHAEL R., PhD, "Integrating Drug Supply Issues with Strategic Preclinical and Clinical Development," Drug Information Journal, 2000, pgs. 909-917, Vol. 34	
		BORCHERT, STEVEN J., RYAN, MICHELE M., DAVISON, RICHARD L., and SPEED, WILLIAM, "Accelerated Extractable Studies of Borosilicate Glass Containers," Research Article, March-April 1989, pgs. 67-79, Vol. 43, No. 2, The Quality Control Division, The Upjohn Company, Kalamazoo, Michigan and Crawley, United Kingdom	
		CACHET, TH., VAN DEN MOOTER, G., HAUCHECORNE, R., VINCKIER, C., and HOOGMARTENS, J., "Decomposition kinetics of erythromycin A in acidic aqueous solutions," International Journal of Pharmaceutics, 55, 1989, pgs. 59-65, Elsevier Science Publishers B.V. (Biomedical Division)	
		CONNORS, KENNETH A. and MOLICA, JOSEPH A., JR., "Theoretical Analysis of Comparative Studies of Complex Formation, Solubility, Spectral, and Kinetic Techniques," Journal of Pharmaceutical Sciences, August 1966, pgs. 772-780, Vol. 55, No. 8	
		ERIKSSON, M., ENGLESSON, S., NIKLASSON F., and HARTVIG, P., "Effect of lignocaine and pH on propofol-induced pain," British Journal of Anaesthesia, 78, 1997, pgs 502-506	
		ERIKSSON, M., ENGLESSON S., and HARTVIG, P., "Acidified propofol retains its anaesthetic potency after storage," European Journal of Anaesthesiology, 16, 1999, pgs 166-168	
		GRUBSTEIN, B. and MILANO, E., "Stabilization of Epinephrine in a Local Anesthetic Injectable Solution Using Reduced Levels of Sodium Metabisulfite and EDTA, Drug Development and Industrial Pharmacy, 18 (14), 1992, pgs 1549-1566, Marcel Dekker, Inc.	

Examiner Signature	Date Considered
-----------------------	--------------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 3 of 5

Complete if Known

Application Number	10/509,627
Filing Date	09/29/04
First Named Inventor	Peggy Wingard et al.
Art Unit	TBD
Examiner Name	TBD
Attorney Docket Number	006050.00067

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		HALL, JOHN C., FRACS, "Glycine," Review, November-December 1998, pgs. 393-397, Vol. 22, No. 6	
		HEM, STANLEY L., RUSSO, EMANUEL J., BAHAL, SURENDRA M., and LEVI, RALPH S., "Kinetic Analysis of Complex Formation between Penicillin and Sucrose," Journal of Pharmaceutical Sciences, February 1973, pgs. 267-270, Vol. 62, No. 2	
		KLEMENT, W., and ARNDT, J.O., "Pain on I.V. Injection of Some Anaesthetic Agents is Evoked by the Unphysiological Osmolality or pH of Their Formulations," British Journal of Anaesthesia, 66, 1991, pgs. 189-195	
		KLEMENT, W., and ARNDT, J.O., "Pain on Injection of Propofol: Effects of Concentration and Diluent," British Journal of Anaesthesia, 67, 1991, pgs. 281-284	
		KRISE, JEFFREY P., NARISAWA, SHINJI, and STELLA, VALENTINO J., "A Novel Prodrug Approach for Tertiary Amines. 2. Physicochemical and in Vitro Enzymatic Evaluation of Selected N-Phosphonoxyethyl Prodrugs," Journal of Pharmaceutical Sciences, September 1999, pgs. 922-927, Vol. 88, No. 9, American Chemical Society and American Pharmaceutical Association	
		LACHMAN, LEON, PAULI, WAYNE A., SHETH, PRAVIN B., and PAGLIERY, MIRIAM, "Lined and Unlined Rubber Stoppers for Multiple-Dose Vial Solutions II, Effect of Teflon lining on Preservative Sorption and Leaching of Extractives," Journal of Pharmaceutical Sciences, September 1966, pgs. 962-966, Vol. 55, No. 9	
		MARTIN, A.J., "pH-adjustment and discomfort caused by the intradermal injection of lignocaine," Forum, Anaesthesia, 1990, pgs 975-978, Vol. 45	
		MENDENHALL, DOUGLAS W., Ph.D., "Stability of Parenterals," Drug Development and Industrial Pharmacy, 10(8&9), 1984, pgs 1297-1342, Marcel Dekker, Inc.	
		BOYLAN, JAMES C. and FITES, ALAN L., "Parenteral Products," Drugs and the Pharmaceutical Sciences, Modern Pharmaceuticals, Second Edition, edited by Gilbert S. Banker and Christopher T. Rhodes, pgs. 491-538, Vol. 40	
		MORRIS, J.M., "Sterilisation Decision Trees Development and Implementation," Commentary, PDA Journal of Pharmaceutical Science & Technology, January-February 2000, pgs 64-68, Vol. 54, No. 1	
		NISHINO, HIROSHI, ITOH NOBUYUKI, NAGASHIMA, MAKIKO, and KUROSAWA, KAZU, "Choice of Manganese(III) Complexes for the Synthesis of 4,4'-Biphenyldiols and 4,4'-Diphenylquinones," Bull. Chem., Soc. Jpn., 1992, pgs. 620-622, Vol. 65, No. 2	


Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 4 of 5

Complete if Known

Application Number	10/509,627
Filing Date	09/29/04
First Named Inventor	Peggy Wingard et al.
Art Unit	TBD
Examiner Name	TBD
Attorney Docket Number	006050.00067

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		PFLUG, IRVING J., and EVANS, KRISTEN D., "Carrying Out Biological Qualification, the Control Operation of Moist-Heat (Steam Sterilization) Processes for Producing Sterile Pharmaceuticals and Medical Devices," PDA Journal of Pharmaceutical Science & Technology, March-April 2000, pgs. 117-135, Vol. 54, No. 2	
		DELUCA, PATRICK P. and BOYLAN, JAMES C., "Formulation of Small Volume Parenterals," Pharmaceutical Dosage Forms: Parenteral Medications, Volume 1, Second Edition, Revised and Expanded, Edited by Kenneth E. Avis, Herbert A. Lieberman, and Leon Lachman, pgs. 173-248	
		PRANKERD, RICHARD and JONES, R. DOUGLAS, "Physicochemical compatibility of propofol with thiopental sodium," Am. J. Health-Syst. Pharm., November 1, 1996, pgs. 2606-2610, Vol. 53	
		REYNOLDS, DAN W., FACCHINE, KEVIN L., MULLANEY, JUNE F., ALSANTE, KAREN M., HATAJIK, TODD D., and MOTTO, MICHAEL G., "Available Guidance and Best Practices for Conducting Forced Degradation Studies," Pharmaceutical Technology, February 2002, pgs. 48-56	
		ROSEMAN, T.J., BROWN, J.A., and SCOTHORN, W.W., "Glass for Parenteral Products: A Surface View Using the Scanning Electron Microscope," Journal of Pharmaceutical Sciences, January 1976, pgs. 22-29, Vol. 65, No. 1	
		ROWE, R.C. WAKERLY, M.G. ROBERTS, R.J. GRUNDY, R.U. and UPJOHN, N.C., "Expert Systems for Parenteral Development," PDA Journal of Pharmaceutical Science & Technology, September-October 1995, pgs. 257-261, Vol. 49, No. 5	
		SOME, ISSA T., BOGAERTS, PHILIPPE, HANUS, RAYMOND, HANOCQ, MICHEL, and DUBOIS, JACQUES, "Stability Parameter Estimation at Ambient Temperature From Studies at Elevated Temperatures," Journal of Pharmaceutical Sciences, November 2001, pgs. 1759-176, Vol. 90, No. 11, Wiley-Liss, Inc. and the American Pharmaceutical Association	
		STEFFANSEN, BENTE and BUNDGAARD, HANS, "Erythromycin prodrugs: kinetics of hydrolysis of erythromycin and various erythromycin 2'-esters in aqueous solution and human plasma," International Journal of Pharmaceutics, 56, 1989, pgs. 159-168, Elsevier Science Publishers B.V. (Biomedical Division)	
		STRICKLEY, ROBERT G., "Parenteral Formulations of Small Molecules Therapeutics Marketed in the United States (1999) - Part I, PDA Journal of Pharmaceutical Science & Technology, November-December 1999, pgs. 324-349, Vol. 53, No. 6	
		STRICKLEY, ROBERT G., "Parenteral Formulations of Small Molecules Therapeutics Marketed in the United States (1999) Part II, PDA Journal of Pharmaceutical Science & Technology, January-February 2000, pgs. 69-96, Vol. 54, No. 1	
		STRICKLEY, ROBERT G., "Parenteral Formulations of Small Molecules Therapeutics Marketed in the United States (1999) Part III, PDA Journal of Pharmaceutical Science & Technology, March-April 2000, pgs. 152-169, Vol. 54, No. 2	

Examiner Signature	Date Considered
-----------------------	--------------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Substitute for form 1449B/PTO


INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 5 of 5

Complete if Known

Application Number	10/509,627
Filing Date	09/29/04
First Named Inventor	Peggy Wingard et al.
Art Unit	TBD
Examiner Name	TBD
Attorney Docket Number	006050.00067



NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		TEMPLETON, ALLEN C., R.-HAN, YIENG-HAU, MAHAJAN, REJIV, CHERN, REY T., and REED, ROBERT A., "Rapid Headspace Oxygen Analysis for Pharmaceutical Packaging Applications," Pharmaceutical Technology, July 2002, pgs. 44-61	
		UGWU, SYDNEY, O. and APTE, SHIREESH P., "Systematic Screening of Antioxidants for Maximum Protection Against Oxidation: An Oxygen Polarograph Study," PDA Journal of Pharmaceutical Science & Technology, September-October 1999, pgs. 252-259, Vol. 53, No. 5	
		VINCKIER, C., HAUCHECORNE, R., CACHET, TH., VAN DEN MOOTER, G., and HOOGMARTENS, J., "A new mechanism for the decomposition of erythromycin A in acidic aqueous solutions," International Journal of Pharmaceutics, 55, 1989, pgs. 67-76, Elsevier Science Publishers B.V. (Biomedical Division)	
		YU, ANDREW B.C. and PORTMANN, GLENN A., "Oxidation Kinetics of an Antiasthmatic, 2-[(4-Hydroxyphenyl)amino]-5-methoxybenzenemethanol, and Stabilization with Ascorbic Acid," Journal of Pharmaceutical Sciences, October 1990, pgs. 913-915, Vol. 79, No. 10, American Pharmaceutical Association	
		YUCHA, CAROLYN B., HASTINGS-TOLSMA, MARIE, and SZEVERENYI, NIKOLAUS M., "Differences Among Intravenous Extravasations Using Four Common Solutions," Journal of Intravenous Nursing, September-October 1993, pgs. 277-281, Vol. 16, No. 5	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.